Ware Olivia C

CIK 00016637714 companiesSAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001663771

Recent Transactions

34 trades

Award
Contineum Therapeutics, Inc.$CTNM
Stock Option (right to buy)
2026-06-26+19,000→ 19,000 total
Disposition to Issuer
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2026-04-28−9,174→ 0 total
Disposition to Issuer
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2026-04-28−8,011→ 0 total
Disposition to Issuer
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2026-04-28−11,459→ 0 total
Disposition to Issuer
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2026-04-28−36,806→ 0 total
Award
Contineum Therapeutics, Inc.$CTNM
Stock Option (right to buy)
2025-06-26+14,750→ 14,750 total
Award
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2025-05-29+9,174→ 9,174 total
Disposition to Issuer
Revance Therapeutics, Inc.
Common Stock
2025-02-06−15,000→ 0 total
Disposition from Tender
Revance Therapeutics, Inc.
Common Stock
2025-02-04$3.65/sh−16,675→ 15,000 total
Award
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2024-05-28+8,011→ 8,011 total
Award
Contineum Therapeutics, Inc.$CTNM
Stock Option (right to buy)
2024-05-24+3,700→ 3,700 total
Award
Revance Therapeutics, Inc.
Common Stock
2024-05-01+15,000→ 31,675 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2024-05-01+23,458→ 23,458 total
Sale
Arcellx, Inc.$ACLX
Common Stock
2024-04-16$56.03/sh−2,612→ 0 total
Exercise/Conversion
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2024-04-16−9,402→ 36,806 total
Exercise/Conversion
Arcellx, Inc.$ACLX
Common Stock
2024-04-16$7.61/sh+9,402→ 9,402 total
Sale
Arcellx, Inc.$ACLX
Common Stock
2024-04-16$55.36/sh−6,790→ 2,612 total
Sale
Arcellx, Inc.$ACLX
Common Stock
2024-03-15$69.44/sh−1,900→ 7,100 total
Sale
Arcellx, Inc.$ACLX
Common Stock
2024-03-15$70.99/sh−3,337→ 0 total
Exercise/Conversion
Arcellx, Inc.$ACLX
Common Stock
2024-03-15$7.61/sh+9,000→ 9,000 total
Exercise/Conversion
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2024-03-15−9,000→ 46,208 total
Sale
Arcellx, Inc.$ACLX
Common Stock
2024-03-15$70.36/sh−3,763→ 3,337 total
Award
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2023-06-14+11,459→ 11,459 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2023-05-03+5,915→ 5,915 total
Award
Revance Therapeutics, Inc.
Common Stock
2023-05-03+3,534→ 16,675 total
Award
Arcellx, Inc.$ACLX
Stock Option (right to buy)
2022-05-16+55,208→ 55,208 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2022-05-04+10,756→ 10,756 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2022-05-04+11,343→ 11,343 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-05-04+6,059→ 13,141 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2021-05-05+1,268→ 1,268 total
Award
Revance Therapeutics, Inc.
Common Stock
2021-05-05+674→ 7,082 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to buy)
2021-03-08+11,161→ 11,161 total
Award
Revance Therapeutics, Inc.
Common Stock
2021-03-08+6,408→ 6,408 total
Award
LadRx Corp$LADX
Stock option (right to buy)
2016-01-11+350,000→ 350,000 total

Companies

Recent Filings

Address

3565 GENERAL ATOMICS COURT, SUITE 200

SAN DIEGO, CA, 92121

View on SEC.gov